Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis
Status:
RECRUITING
Trial end date:
2024-09-20
Target enrollment:
Participant gender:
Summary
Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.